EVOMMUNE INC (EVMN) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 8, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the EVMN SEC filings page.
EVOMMUNE INC (EVMN) reported $13.0M in revenue for fiscal year 2025, up 85.7% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
EVMN’s dominant mechanic is development-stage spending financed by a balance-sheet reset rather than operating cash generation.
Revenue nearly doubled by FY2025, yet operating cash flow worsened to-$76.4M , showing that greater scale has not translated into internally generated cash. R&D was$74M against$13M of revenue, while free cash flow nearly matched operating cash flow, indicating the shortfall is primarily operating investment rather than heavy capital expenditure.
In FY2025, liabilities were
The current ratio rose from 2.6x to 8.6x, indicating substantially more current assets relative to near-term obligations. Yet FY2025 operating cash flow was
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of EVOMMUNE INC's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
EVOMMUNE INC's reported operating margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 22/100.
EVOMMUNE INC's revenue surged 85.7% year-over-year to $13.0M, reflecting rapid business expansion. This strong growth earns a score of 98/100.
EVOMMUNE INC carries a low D/E ratio of 0.09, meaning only $0.09 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 81/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 8.57, EVOMMUNE INC holds $8.57 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 97/100.
EVOMMUNE INC's reported free cash flow margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 1/100.
EVOMMUNE INC posts a -33.5% return on equity (ROE), meaning it loses $34 for every $100 of shareholders' equity. This results in a returns score of 18/100.
EVOMMUNE INC scores 12.91, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($474.7M) relative to total liabilities ($19.4M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
EVOMMUNE INC passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
EVOMMUNE INC reported a net loss of $68.9M while operations used $76.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
EVOMMUNE INC generated $0 in revenue in Q2 2026.
EVOMMUNE INC's EBITDA was -$34.7M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 52.2% from the same quarter a year earlier. Against the prior quarter it is down 45.4%.
EVOMMUNE INC reported -$32.2M in net income in Q2 2026. This represents a decrease of 137.7% from the same quarter a year earlier. Against the prior quarter it is down 48.8%.
EVOMMUNE INC earned -$0.89 per diluted share (EPS) in Q2 2026. Against the prior quarter it is down 39.1%.
Cash & Balance Sheet
EVOMMUNE INC recorded an outflow of $20.5M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 21.8% from the same quarter a year earlier. Against the prior quarter it is up 25.7%.
EVOMMUNE INC held $60.0M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
EVOMMUNE INC's ROE was -11.6% in Q2 2026, measuring profit generated per dollar of shareholder equity. Against the prior quarter it is down 4.5 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
EVOMMUNE INC invested $26.4M in research and development in Q2 2026. This represents an increase of 34.5% from the same quarter a year earlier. Against the prior quarter it is up 52.5%.
EVOMMUNE INC invested $183K in capex in Q2 2026, funding long-term assets and infrastructure. Against the prior quarter it is up 120.5%.
Not reported for Q2 2026.
EVMN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0-100.0% | N/A | $10.0M | $0 | $3.0M | N/A | N/A |
| R&D Expenses | $26.4M+34.5% | $17.3M+20.6% | N/A | $19.6M+47.8% | $19.6M | $14.4M | N/A | $13.3M |
| SG&A Expenses | $8.5M+152.8% | $6.6M+80.8% | N/A | $3.7M+14.3% | $3.4M | $3.7M | N/A | $3.2M |
| Operating Income | -$34.9M-51.8% | -$24.0M-59.4% | N/A | -$13.3M+19.3% | -$23.0M | -$15.0M | N/A | -$16.5M |
| EBITDA | -$34.7M-52.2% | -$23.9M-60.8% | N/A | N/A | -$22.8M | -$14.8M | N/A | N/A |
| Income Tax | N/A | $0 | N/A | $0 | N/A | $0 | N/A | $0 |
| Net Income | -$32.2M-137.7% | -$21.7M-48.9% | N/A | -$12.5M+21.6% | -$13.6M | -$14.6M | N/A | -$15.9M |
| EPS (Basic) | -$0.89+89.9% | -$0.64+93.2% | $15.14+203.7% | -$8.07+22.9% | -$8.80 | -$9.48 | -$14.60 | -$10.47 |
| EPS (Diluted) | -$0.89 | -$0.64 | $15.14 | -$8.07+22.9% | -$8.80 | -$9.48 | -$14.60 | -$10.47 |
| Diluted Shares (Avg) | 36M | 34M | N/A | 2M+1.6% | 2M | 2M | N/A | 2M |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.
EVMN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $301.9M | $322.5M | $224.9M+195.8% | $84.5M | N/A | N/A | $76.1M | N/A |
| Current Assets | $204.2M | $215.9M | $153.5M+107.4% | $81.9M | N/A | N/A | $74.0M | N/A |
| Cash & Equivalents | $60.0M-2.9% | $48.3M+747.1% | $44.1M+171.1% | $26.8M+47.8% | $61.8M | $5.7M | $16.3M | $18.1M |
| Short-Term Investments | $140.8M | $163.1M | $105.1M+88.5% | $49.2M | $0 | $0 | $55.8M | $0 |
| Long-Term Investments | $87.2M | $95.5M | $67.5M | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $24.4M | $17.9M | $19.4M-91.2% | $267.7M | N/A | N/A | $220.3M | N/A |
| Current Liabilities | $17.5M | $10.6M | $17.9M-36.0% | $10.4M | N/A | N/A | $28.0M | N/A |
| Non-Current Liabilities | $6.9M | $7.3M | $1.5M-99.2% | $257.3M | N/A | N/A | $192.3M | N/A |
| Total Equity | $277.6M+262.1% | $304.6M+292.5% | $205.6M+242.5% | -$183.1M-49.5% | -$171.2M | -$158.2M | -$144.2M | -$122.5M |
| Retained Earnings | -$275.0M | -$242.8M | -$221.1M-45.2% | -$192.8M | N/A | N/A | -$152.2M | N/A |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
EVMN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$20.3M+22.5% | -$27.5M-15.1% | -$16.7M+9.8% | -$9.6M | -$26.2M | -$23.9M | -$18.5M | N/A |
| Depreciation & Amortization | $200K0.0% | $100K-50.0% | N/A | N/A | $200K | $200K | N/A | N/A |
| Stock-Based Compensation | $4.6M+725.5% | $3.5M+534.9% | N/A | $561K+39.9% | $557K | $544K | N/A | $401K |
| Capital Expenditures | $183K | $83K | $104K | $131K | $0 | $0 | $0 | N/A |
| Free Cash Flow | -$20.5M+21.8% | -$27.6M-15.4% | -$16.8M+9.2% | -$9.8M | -$26.2M | -$23.9M | -$18.5M | N/A |
| Investing Cash Flow | $31.3M+73.9% | -$85.4M-732.3% | -$122.9M-271.5% | -$23.9M | $18.0M | $13.5M | -$33.1M | N/A |
| Financing Cash Flow | $532K-99.2% | $117.1M+77146.7% | $156.8M+215.6% | -$274K | $64.3M | -$152K | $49.7M | N/A |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
EVMN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | N/A | N/A | N/A | -133.3% | N/A | -501.1% | N/A | N/A |
| Net Margin | N/A | N/A | N/A | -124.8% | N/A | -485.2% | N/A | N/A |
| Return on Equity | -11.6% | -7.1% | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -10.7% | -6.7% | N/A | -14.8% | N/A | N/A | N/A | N/A |
| Current Ratio | 11.68 | 20.36 | 8.57+5.9x | 7.87 | N/A | N/A | 2.64 | N/A |
| Debt-to-Equity | 0.09 | 0.06 | 0.09 | N/A | N/A | N/A | N/A | N/A |
| Asset Turnover | 0.00 | 0.00 | N/A | 0.12 | N/A | N/A | N/A | N/A |
| FCF Margin | N/A | N/A | N/A | -97.7% | N/A | -796.6% | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Where EVOMMUNE INC Ranks
Frequently Asked Questions
What is EVOMMUNE INC's annual revenue?
EVOMMUNE INC (EVMN) reported $13.0M in total revenue for fiscal year 2025. This represents a 85.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is EVOMMUNE INC's revenue growing?
EVOMMUNE INC (EVMN) revenue grew by 85.7% year-over-year, from $7.0M to $13.0M in fiscal year 2025.
Is EVOMMUNE INC profitable?
No, EVOMMUNE INC (EVMN) reported a net income of -$68.9M in fiscal year 2025.
What is EVOMMUNE INC's EBITDA?
EVOMMUNE INC (EVMN) had EBITDA of -$80.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is EVOMMUNE INC's return on equity (ROE)?
EVOMMUNE INC (EVMN) has a return on equity of -33.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is EVOMMUNE INC's free cash flow?
EVOMMUNE INC (EVMN) recorded an outflow of $76.7M in free cash flow during fiscal year 2025. This represents a -31.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is EVOMMUNE INC's operating cash flow?
EVOMMUNE INC (EVMN) recorded an outflow of $76.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are EVOMMUNE INC's total assets?
EVOMMUNE INC (EVMN) had $224.9M in total assets as of fiscal year 2025, including both current and long-term assets.
What are EVOMMUNE INC's capital expenditures?
EVOMMUNE INC (EVMN) invested $235K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does EVOMMUNE INC spend on research and development?
EVOMMUNE INC (EVMN) invested $74.0M in research and development during fiscal year 2025.
What is EVOMMUNE INC's current ratio?
EVOMMUNE INC (EVMN) had a current ratio of 8.57 as of fiscal year 2025, which is generally considered healthy.
What is EVOMMUNE INC's debt-to-equity ratio?
EVOMMUNE INC (EVMN) had a debt-to-equity ratio of 0.09 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is EVOMMUNE INC's return on assets (ROA)?
EVOMMUNE INC (EVMN) had a return on assets of -30.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is EVOMMUNE INC's P/E ratio?
EVOMMUNE INC (EVMN) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $474.7M as of Sep 8, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is EVOMMUNE INC's price-to-sales ratio?
EVOMMUNE INC (EVMN) trades at 36.5x sales, its market capitalization divided by revenue of $13.0M revenue, FY2025. The market capitalization is $474.7M as of Sep 8, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does EVOMMUNE INC's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, EVOMMUNE INC (EVMN) held $216.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $76.4M over that year. Dividing the one by the other, the reported balance equals about 34 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is EVOMMUNE INC's Altman Z-Score?
EVOMMUNE INC (EVMN) has an Altman Z-Score of 12.91, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is EVOMMUNE INC's Piotroski F-Score?
EVOMMUNE INC (EVMN) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are EVOMMUNE INC's earnings high quality?
EVOMMUNE INC (EVMN) reported a net loss of $68.9M while operations used $76.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is EVOMMUNE INC?
EVOMMUNE INC (EVMN) scores 53 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.